2019
PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway
Padhani AR, Barentsz J, Villeirs G, Rosenkrantz AB, Margolis DJ, Turkbey B, Thoeny HC, Cornud F, Haider M, Macura K, Tempany C, Verma S, Weinreb J. PI-RADS Steering Committee: The PI-RADS Multiparametric MRI and MRI-directed Biopsy Pathway. Radiology 2019, 292: 464-474. PMID: 31184561, PMCID: PMC6677282, DOI: 10.1148/radiol.2019182946.Peer-Reviewed Original ResearchConceptsBiopsy pathwayProstate cancerLife-threatening prostate cancerBiopsy-naive menNegative biopsy resultsClinical care guidelinesHigh-quality evidenceSignificant prostate cancerRoutine clinical practiceProstate Imaging ReportingGreater clinical utilityNumber of diagnosesProstate cancer detectionClinical suspicionInsignificant cancerCare guidelinesBiopsy resultsProstate biopsyTransrectal USMRI pathwayPositive health impactsNumber of menBiopsy increasesIncorporation of MRIClinical utility
2016
MRI-US fusion targeted biopsy results in patients without history of prostate biopsy.
Nawaf C, Rosoff J, Weinreb J, Lu A, Levi A, Humphrey P, Schulam P, Sprenkle P. MRI-US fusion targeted biopsy results in patients without history of prostate biopsy. Journal Of Clinical Oncology 2016, 34: 150-150. DOI: 10.1200/jco.2016.34.2_suppl.150.Peer-Reviewed Original ResearchBiopsy-naive menMRI-US fusionGleason scoreProstate cancerMapping biopsyProstate biopsyCS prostate cancerPre-biopsy mpMRITemplate mapping biopsyLow-grade diseaseCancer detection rateMRI-ultrasound fusionBiopsy of lesionsMaximum Gleason scoreCS cancerPrevious biopsyPrior biopsyBiopsy resultsFusion biopsyInclusion criteriaMp-MRIPatient basisPatientsBiopsyCancerProstate cancer detection rates of negative MP-MRIs.
Lu A, Nawaf C, Weinreb J, Rosoff J, Schulam P, Humphrey P, Levi A, Sprenkle P. Prostate cancer detection rates of negative MP-MRIs. Journal Of Clinical Oncology 2016, 34: 91-91. DOI: 10.1200/jco.2016.34.2_suppl.91.Peer-Reviewed Original ResearchTemplate mapping biopsyNegative predictive valueNegative MRIMapping biopsyActive surveillanceSignificant cancerProstate cancer detection rateSignificant CaPMRI-US fusion biopsyHigh negative predictive valueBiopsy-naive menPrior negative biopsyBiopsy-naïve patientsCancer detection rateProstate cancer detectionDiffusion-weighted imagingDynamic contrast enhancementNIH National InstituteNaïve patientsNegative menGleason 7High suspicionNegative biopsyPatient counselingGleason 4